LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,573
تعداد دریافت فایل اصل مقاله11,291,392
Ghasemiyeh, Parisa, Mohammadi-Samani, Soliman. (1399). Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19?. سامانه مدیریت نشریات علمی, 6(2), 65-66. doi: 10.30476/tips.2020.86274.1047
Parisa Ghasemiyeh; Soliman Mohammadi-Samani. "Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19?". سامانه مدیریت نشریات علمی, 6, 2, 1399, 65-66. doi: 10.30476/tips.2020.86274.1047
Ghasemiyeh, Parisa, Mohammadi-Samani, Soliman. (1399). 'Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19?', سامانه مدیریت نشریات علمی, 6(2), pp. 65-66. doi: 10.30476/tips.2020.86274.1047
Ghasemiyeh, Parisa, Mohammadi-Samani, Soliman. Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19?. سامانه مدیریت نشریات علمی, 1399; 6(2): 65-66. doi: 10.30476/tips.2020.86274.1047

Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19?

Trends in Pharmaceutical Sciences
مقاله 1، دوره 6، شماره 2، شهریور 2020، صفحه 65-66    اصل مقاله (269.07 K)
نوع مقاله: Letter to The Editor
شناسه دیجیتال (DOI): 10.30476/tips.2020.86274.1047
نویسندگان
Parisa Ghasemiyeh1؛ Soliman Mohammadi-Samani* 2
1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
2Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
چکیده
Dear Editor,
On December 2019, new cases of COVID-19 pneumonia were reported from Wuhan city of China that were consequences of 2019-nCoV or SARS-CoV-2 infection (1). Very soon this disease spread around the world and till now over than 3,000,000 person have been infected with this new virus. The most common clinical presentations of these patients were fever, dry cough, malaise, fatigue, myalgia, headache, shortness of breath, chest pain, ageusia, anosmia, gastrointestinal, cerebrovascular and dermatologic presentations (2-4). Since COVID-19 is a new disease, there isn’t any approved treatment regimen. Till now many drugs have been studied under clinical trials projects such as (hydroxyl)chloroquine, azithromycin, ribavirin, lopinavir/ritonavir, atazanavir, umofenovir, favipiravir, remdesivir, interferon alpha, tocilizumab, etc (5). Also many supportive therapies have been considered such as convalescent plasma therapy (6), high dose intravenous vitamin C therapy (7), extracorporeal membrane oxygenation (ECMO), etc. (8).
Severe cases of COVID-19, have accompanied tachypnea, shortness of breath, oxygen saturation levels of less than 90%, acute respiratory distress syndrome (ARDS), sepsis, septic shock and multi-organ failure (especially heart, kidney and liver damage).
کلیدواژه‌ها
COVID-19؛ SARS-CoV-2؛ Iron chelating agents؛ Deferoxamine؛ Severe cases
آمار
تعداد مشاهده مقاله: 11,381
تعداد دریافت فایل اصل مقاله: 1,547


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب